133 related articles for article (PubMed ID: 28859044)
1. Vincristine, Irinotecan, and Bevacizumab in Relapsed Wilms Tumor With Diffuse Anaplasia.
Schiavetti A; Varrasso G; Collini P; Clerico A
J Pediatr Hematol Oncol; 2018 May; 40(4):331-333. PubMed ID: 28859044
[TBL] [Abstract][Full Text] [Related]
2. Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab.
Venkatramani R; Malogolowkin MH; Mascarenhas L
Pediatr Blood Cancer; 2014 Apr; 61(4):756-9. PubMed ID: 24115645
[TBL] [Abstract][Full Text] [Related]
3. Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group.
Green DM; Beckwith JB; Breslow NE; Faria P; Moksness J; Finklestein JZ; Grundy P; Thomas PR; Kim T; Shochat S
J Clin Oncol; 1994 Oct; 12(10):2126-31. PubMed ID: 7931483
[TBL] [Abstract][Full Text] [Related]
4. Maintenance chemotherapy to reduce the risk of a metachronous Wilms tumor in children with bilateral nephroblastomatosis.
Ortiz MV; Fernandez-Ledon S; Ramaswamy K; Forlenza CJ; Shukla NN; Kobos R; Heaton TE; LaQuaglia MP; Steinherz PG
Pediatr Blood Cancer; 2019 Jan; 66(1):e27500. PubMed ID: 30334607
[TBL] [Abstract][Full Text] [Related]
5. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study.
Tournade MF; Com-Nougué C; de Kraker J; Ludwig R; Rey A; Burgers JM; Sandstedt B; Godzinski J; Carli M; Potter R; Zucker JM;
J Clin Oncol; 2001 Jan; 19(2):488-500. PubMed ID: 11208843
[TBL] [Abstract][Full Text] [Related]
6. Focal versus diffuse anaplasia in Wilms tumor--new definitions with prognostic significance: a report from the National Wilms Tumor Study Group.
Faria P; Beckwith JB; Mishra K; Zuppan C; Weeks DA; Breslow N; Green DM
Am J Surg Pathol; 1996 Aug; 20(8):909-20. PubMed ID: 8712292
[TBL] [Abstract][Full Text] [Related]
7. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
Büyükkapu Bay S; Kebudi R; Görgün O; Zülfikar B; Darendeliler E; Çakır FB
J Oncol Pharm Pract; 2019 Sep; 25(6):1343-1348. PubMed ID: 30080131
[TBL] [Abstract][Full Text] [Related]
8. New definitions of focal and diffuse anaplasia in Wilms tumor: the International Society of Paediatric Oncology (SIOP) experience.
Vujanić GM; Harms D; Sandstedt B; Weirich A; de Kraker J; Delemarre JF
Med Pediatr Oncol; 1999 May; 32(5):317-23. PubMed ID: 10219330
[TBL] [Abstract][Full Text] [Related]
9. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.
Dome JS; Cotton CA; Perlman EJ; Breslow NE; Kalapurakal JA; Ritchey ML; Grundy PE; Malogolowkin M; Beckwith JB; Shamberger RC; Haase GM; Coppes MJ; Coccia P; Kletzel M; Weetman RM; Donaldson M; Macklis RM; Green DM
J Clin Oncol; 2006 May; 24(15):2352-8. PubMed ID: 16710034
[TBL] [Abstract][Full Text] [Related]
10. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group.
Green DM; Breslow NE; Beckwith JB; Finklestein JZ; Grundy PE; Thomas PR; Kim T; Shochat SJ; Haase GM; Ritchey ML; Kelalis PP; D'Angio GJ
J Clin Oncol; 1998 Jan; 16(1):237-45. PubMed ID: 9440748
[TBL] [Abstract][Full Text] [Related]
11. Treatment of patients with stage I focal anaplastic and diffuse anaplastic Wilms tumour: A report from the SIOP-WT-2001 GPOH and UK-CCLG studies.
Mifsud W; Furtwängler R; Vokuhl C; D'Hooghe E; Pritchard-Jones K; Graf N; Vujanić GM
Eur J Cancer; 2022 May; 166():1-7. PubMed ID: 35255331
[TBL] [Abstract][Full Text] [Related]
12. [Wilms' tumour of unfavorable histology--results of treatment with the SIOP 93-01 protocol at the Gdańsk centre. Preliminary report].
Stefanowicz J; Sierota D; Balcerska A; Stoba C
Med Wieku Rozwoj; 2004; 8(2 Pt 1):197-200. PubMed ID: 15738594
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group.
Malogolowkin M; Cotton CA; Green DM; Breslow NE; Perlman E; Miser J; Ritchey ML; Thomas PR; Grundy PE; D'Angio GJ; Beckwith JB; Shamberger RC; Haase GM; Donaldson M; Weetman R; Coppes MJ; Shearer P; Coccia P; Kletzel M; Macklis R; Tomlinson G; Huff V; Newbury R; Weeks D;
Pediatr Blood Cancer; 2008 Feb; 50(2):236-41. PubMed ID: 17539021
[TBL] [Abstract][Full Text] [Related]
14. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for local recurrence in Wilms tumour and the potential influence of biopsy - the United Kingdom experience.
Irtan S; Jitlal M; Bate J; Powis M; Vujanic G; Kelsey A; Walker J; Mitchell C; Machin D; Pritchard-Jones K;
Eur J Cancer; 2015 Jan; 51(2):225-32. PubMed ID: 25465191
[TBL] [Abstract][Full Text] [Related]
16. Nephroblastomatosis update.
Laberge JM
Med Pediatr Oncol; 2003 Jul; 41(1):96-7. PubMed ID: 12764764
[No Abstract] [Full Text] [Related]
17. Bilateral Wilms' tumor with anaplasia: lessons from the National Wilms' Tumor Study.
Hamilton TE; Green DM; Perlman EJ; Argani P; Grundy P; Ritchey ML; Shamberger RC
J Pediatr Surg; 2006 Oct; 41(10):1641-4. PubMed ID: 17011261
[TBL] [Abstract][Full Text] [Related]
18. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial.
de Kraker J; Graf N; van Tinteren H; Pein F; Sandstedt B; Godzinski J; Tournade MF;
Lancet; 2004 Oct 2-8; 364(9441):1229-35. PubMed ID: 15464183
[TBL] [Abstract][Full Text] [Related]
19. Preservation of anaplastic features in Wilms' tumors after preoperative chemotherapy.
Alvarez-Silvan AM; Gavilan Carrasco F; Pineda Cuevas G; Andrade Becerra E; Anguita ML; Martinez Caro A; Gracia Valles MC; Maillo Arcega MA
Med Pediatr Oncol; 1989; 17(2):131-3. PubMed ID: 2539546
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.
Robles AJ; Kurmasheva RT; Bandyopadhyay A; Phelps DA; Erickson SW; Lai Z; Kurmashev D; Chen Y; Smith MA; Houghton PJ
Clin Cancer Res; 2020 Jun; 26(12):3012-3023. PubMed ID: 32184294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
